Fulcrum Therapeutics/$FULC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fulcrum Therapeutics
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Ticker
$FULC
Sector
Primary listing
Employees
45
Headquarters
Website
FULC Metrics
BasicAdvanced
$503M
-
-$1.18
2.38
-
Price and volume
Market cap
$503M
Beta
2.38
52-week high
$9.89
52-week low
$2.32
Average daily volume
508K
Financial strength
Current ratio
24.415
Quick ratio
23.978
Long term debt to equity
2.462
Total debt to equity
3.532
Profitability
EBITDA (TTM)
-81.275
Management effectiveness
Return on assets (TTM)
-19.76%
Return on equity (TTM)
-30.00%
Valuation
Price to book
2.34
Price to tangible book (TTM)
2.34
Price to free cash flow (TTM)
-8.858
Free cash flow yield (TTM)
-11.29%
Free cash flow per share (TTM)
-1.049
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
261.44%
3-year earnings per share growth (CAGR)
-23.39%
What the Analysts think about FULC
Analyst ratings (Buy, Hold, Sell) for Fulcrum Therapeutics stock.
Bulls say / Bears say
The 12 mg cohort of the Phase 1b PIONEER trial showed a robust 8.6% mean increase in fetal hemoglobin at 12 weeks and evidence of pan-cellular induction, with encouraging trends in fewer vaso-occlusive crises. (GlobeNewswire)
Fulcrum ended Q2 2025 with $214.1 million in cash, cash equivalents, and marketable securities, extending its runway into 2028 and supporting further clinical development. (GlobeNewswire)
Pociredir has been granted FDA Fast Track designation and Orphan Drug Designation for sickle cell disease, facilitating an expedited development path and potential market exclusivity. (GlobeNewswire)
Fulcrum reported a net loss of $17.3 million in Q2 2025, compared to net income of $55.4 million in Q2 2024, highlighting ongoing profitability challenges. (GlobeNewswire)
Collaboration revenue fell to zero in Q2 2025 from $80.0 million in Q2 2024, underscoring revenue concentration risk and the impact of the Sanofi deal’s completion. (GlobeNewswire)
Cash and equivalents decreased by $26.9 million from December 31, 2024 to June 30, 2025 due to operating activities, reflecting a high cash burn rate that could pressure financing needs. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
FULC Financial Performance
Revenues and expenses
FULC Earnings Performance
Company profitability
FULC News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fulcrum Therapeutics stock?
Fulcrum Therapeutics (FULC) has a market cap of $503M as of October 17, 2025.
What is the P/E ratio for Fulcrum Therapeutics stock?
The price to earnings (P/E) ratio for Fulcrum Therapeutics (FULC) stock is 0 as of October 17, 2025.
Does Fulcrum Therapeutics stock pay dividends?
No, Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders as of October 17, 2025.
When is the next Fulcrum Therapeutics dividend payment date?
Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders.
What is the beta indicator for Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) has a beta rating of 2.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.